Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma-Reference-Cited by-同舟云学术

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma

Published:2009-08-01 Issue:15 Volume:115 Page:3468-3474
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Satoh Takefumi,Kimura Masaki,Matsumoto Kazumasa,Tabata Ken-ichi,Okusa Hiroshi,Bessho Hideharu,Iwamura Masatsugu,Ishiyama Hiromichi,Hayakawa Kazushige,Baba Shiro

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24404/fullpdf

Reference21 articles.

1. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE);Kawakami;Cancer.,2006

2. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma;Shahinian;Cancer.,2005

3. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective [review];Akaza;Cancer Sci.,2006

4. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy;Berruti;J Urol.,2002

5. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer;Greenspan;J Clin Endocrinol Metab.,2005

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: A longitudinal observational study (The ANTELOPE Study);Journal of Bone Oncology;2024-08

2. The relationship between serum testosterone and bone mineral density in Japanese men and the effects zoledronic acid in prostate cancer patients with low serum testosterone;Journal of Men's Health;2024

3. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer;Journal of Bone and Mineral Metabolism;2023-04-10

4. Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials;PLOS ONE;2022-09-22

5. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR;Journal of Bone and Mineral Metabolism;2020-02-04